News

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y

Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instrument company Bruker (NASDAQ:BRKR). announced better-than-expected revenue in Q1 CY2026, with sales up 2.7% year on year to $823.4 million. The company expects the full year’s revenue to be around $3.59 billion, close to analysts’ estimates. Its non-GAAP profit of $0.31 per share was 34.8% above analysts’ consensus estimates.

Bruker recently saw its shares weaken further as investors weighed an upcoming Q1 earnings report and fresh insider selling activity against current valuation metrics suggesting the stock is trading below one estimate of intrinsic value. The combination of flat year-on-year revenue expectations, past revenue guidance that exceeded forecasts despite an EPS miss, and a gap to intrinsic value estimates is sharpening focus on whether the forthcoming results can shift sentiment. With analysts...

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.It was about worms. Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, here’s where things get interesting for us. For deca

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 5%.

If you are wondering whether Bruker at around US$40 a share is a fair deal or not, you are in the right place for a closer look at what the current price might imply. The stock has returned 0.5% over the last 7 days and 20.2% over the last 30 days, but year to date it is sitting on a 16.7% decline and the 3 year and 5 year returns of 47.3% and 41.8% declines tell a different story to the 9.1% gain over the last year. Recent news coverage has focused on Bruker as part of longer term industry...

A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.

Shares of scientific instrument company Bruker (NASDAQ:BRKR). jumped 4% in the afternoon session after the company announced new Nuclear Magnetic Resonance (NMR) products and workflow solutions at the Experimental Nuclear Magnetic Resonance Conference.

Bruker (BRKR) is back in focus after announcing accelerated work on its photothermal AFM-IR spectroscopy, including a new collaboration with semiconductor research hub imec built around the Dimension IconIR system. See our latest analysis for Bruker. The recent semiconductor focused AFM-IR announcement and the addition of an experienced diagnostics executive to the board come after a sharp 90 day share price return decline of 30.82% and a much weaker 3 year total shareholder return decline of...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

BRKR faces macro and currency headwinds, but strong BSI Nano growth, AI-driven demand and BioSpin innovations support its long-term outlook.

Bruker’s fair value estimate has been trimmed slightly from US$48.43 to US$47.86 per share, signaling a modest reset in modeled upside. This small move lines up with mixed analyst commentary, where some are encouraged by longer term growth targets while others focus on margin execution, helium related input costs, and peer multiple compression when revisiting price targets. As you read on, you will see how these shifting views fit together and what to watch as the Bruker story continues to...